Below is Validea’s ETF fundamental report for VanEck Retail ETF (RTH). The report looks at RTH’s exposure to Read More
Below is Validea’s ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH’s exposure to Read More
With 2023 now more than half over, investors might be wondering where the next big market opportunities can be found. Companies Read More
Institutional investors and a growing number of sell-side analysts are turning positive on DraftKings (US:DKNG), which owns and operates Read More
Institutional investors and a growing number of sell-side analysts are turning positive on DraftKings (US:DKNG), which owns and operates Read More
Artificial intelligence predicts that Palantir Technologies (NYSE:PLTR) stock will move higher. Plus, a well-known fund manager likes Palantir Technologies’ Read More
According to delivery data, China-based electric vehicle manufacturer Nio (NYSE:NIO) isn’t firing on all cylinders. Yet, there’s Read More
About 1,322 shares advanced, 2,037 declined and 129 remained unchanged on July 13. The Indian equity benchmarks closed in the green on July 13, with Read More
On July 12, 2023 at 09:40:08 ET an unusually large $322.34K block of Call contracts in SLB (SLB) was bought, with a strike Read More
On July 12, 2023 at 09:40:08 ET an unusually large $322.34K block of Call contracts in SLB (SLB) was bought, with a strike Read More
On July 12, 2023 at 09:43:36 ET an unusually large $944.49K block of Call contracts in KraneShares Trust – KraneShares CSI China Internet ETF (Read More
On July 12, 2023 at 09:43:36 ET an unusually large $944.49K block of Call contracts in KraneShares Trust – KraneShares CSI China Internet ETF (Read More
On July 12, 2023 at 10:00:52 ET an unusually large $790.72K block of Call contracts in TJX Companies (TJX) was sold, with a Read More
On July 12, 2023 at 10:00:52 ET an unusually large $790.72K block of Call contracts in TJX Companies (TJX) was sold, with a Read More
UBS upgraded AstraZeneca ‘s stock to a “buy” rating despite the drugmaker’s trial of a lung cancer medication recently Read More
UBS upgraded AstraZeneca ‘s stock to a “buy” rating despite the drugmaker’s trial of a lung cancer medication recently Read More
SBI Securities has a target of Rs 651 on the stock, valuing it at 42 times its one-year forward earnings . ‘); $(‘#lastUpdated_’+articleId).Read More
SBI Securities has a target of Rs 651 on the stock, valuing it at 42 times its one-year forward earnings . ‘); $(‘#lastUpdated_’+articleId).Read More
Hindalco Industries is down nearly 8 percent in the year so far, sharply underperforming the Nifty 50’s near 7.5 percent rise during Read More
Hindalco Industries is down nearly 8 percent in the year so far, sharply underperforming the Nifty 50’s near 7.5 percent rise during Read More